StocksMedium•29 September 2026•
1 min read
Immix Biopharma Shares Rise on Positive AL Amyloidosis Trial Results
Key Facts
1Immix Biopharma shares rose following the release of new mid-stage clinical trial data for its AL amyloidosis therapy.
Immix Biopharma shares rose following the release of new mid-stage clinical trial data for its AL amyloidosis therapy. Seeking Alpha reported that the positive update concerns NXC-201, the company's lead asset for treating the rare disorder characterized by multi-organ failure.
The positive clinical data provides a potential path toward regulatory approval and commercialization of this specialized therapy. The stock trended higher during premarket trading on September 29, 2026, even as the company announced a $125 million stock offering.